| | | Right distal radial access (n = 91) | Left distal radial access (n = 91) | value |
| | Age, (years), mean (SD) | 67.9 (11.3) | 69.05 (11.8) | 0.501 | | Female gender, n (%) | 30 (33.0%) | 33 (36.3%) | 0.640 | | BMI, (kg/m2), mean (SD) | 27.35 (4.8) | 27.03 (4.28) | 0.634 | | Hypertension, n (%) | 63 (69.2%) | 66 (72.5%) | 0.625 | | Dyslipidemia, n (%) | 50 (54.9%) | 47 (51.6) | 0.656 | | Diabetes mellitus, n (%) | 29 (31.9%) | 29 (31.9%) | 1.0 | | Smoking habit | | | 0.114 | | Nonsmoker, n (%) | 48 (52.7%) | 62 (68.1%) | | | Previous smoker, n (%) | 28 (30.8%) | 18 (19.8%) | | | Current smoker, n (%) | 15 (16.5%) | 11 (12.1%) | | | Family history of ischemic heart disease, n (%) | 3 (3.3%) | 6 (6.6%) | 0.305 | | Previous MI, n (%) | 17 (18.7%) | 15 (16.5%) | 0.353 | | Previous stroke, n (%) | 4 (4.4%) | 1 (1.1%) | 0.174 | | Previous heart failure, n (%) | 28 (30.8%) | 30 (33.0%) | 0.750 | | GFR (ml/minute/1.73 m2), mean (SD) | 77.7 (16.2) | 73.8 (17.2) | 0.116 | | LVEF, mean (SD) | 52 (17.1) | 55 (15.8) | 0.169 | | Atrial fibrillation, n (%) | 13 (14.3%) | 21 (23.1%) | 0.128 | | OAT | | | 0.697 | | Acenocoumarol, n (%) | 11 (12.1%) | 12 (13.2%) | | | Dabigatran, n (%) | 1 (1.1%) | 1 (1.1%) | | | Apixaban, n (%) | 3 (3.3%) | 6 (6.6%) | | | Edoxaban, n (%) | 0 (0%) | 1 (1.1%) | |
|
|
SD, standard deviation; BMI, body mass index; MI, myocardial infarction; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; OAT, oral anticoagulation therapy.
|
